NFKB1 and plasma cell myeloma: Combination therapy simultaneously targeting NIK and IKKβ (as a main kinase of the canonical NF-κB pathway), either using the selective NIK inhibitors (AM-0216 or AM-0561) and a small molecule IKKβ inhibitor (MLX) [278] or the promising dual inhibitor of NIK and IKKβ, PBS-1086 [277], showed significant anti-multiple myeloma activity, associated with apoptosis and inhibition of both NF-κB pathways in tumor cells in vitro [277, 278] and in a mouse xenograft model of human multiple myeloma [277].